Clinical trial
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and…
NCT04639362 · Stichting Hemato-Oncologie voor Volwassenen Nederland, Other · Active, not recruiting
Key facts
| NCT number | NCT04639362 |
|---|---|
| Title | CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. |
| Official title | First Line Treatment With VeNEtoclaX and ibruTinib Induction Followed by Obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients Not in Complete Remission and/or With Detectable Bone Marrow Minimal Residual Disease (NEXT STEP Trial) |
| Lead sponsor | Stichting Hemato-Oncologie voor Volwassenen Nederland, Other |
| Collaborators | Nordic Lymphoma Group |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | CLL |
| Intervention type | Drug |
| Interventions | ibrutinib, venetoclax, obinutuzumab |
| Enrollment | 85 |
| Start date | Dec 29, 2020 |
| Primary completion | Dec 1, 2025 |
| Completion | Dec 1, 2028 |
| First posted | Nov 20, 2020 |
| Last update posted | Aug 23, 2021 |
| Countries | Denmark, Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: